Q3 EPS Estimate for Dr. Reddy’s Laboratories Cut by Analyst

Dr. Reddy’s Laboratories Ltd (NYSE:RDY) – Equities researchers at Zacks Research reduced their Q3 2027 earnings estimates for shares of Dr. Reddy’s Laboratories in a research report issued on Tuesday, June 2nd. Zacks Research analyst Team now forecasts that the company will earn $0.12 per share for the quarter, down from their prior estimate of $0.13. The consensus estimate for Dr. Reddy’s Laboratories’ current full-year earnings is $0.53 per share. Zacks Research also issued estimates for Dr. Reddy’s Laboratories’ Q4 2027 earnings at $0.05 EPS, FY2027 earnings at $0.51 EPS, Q2 2028 earnings at $0.15 EPS, Q3 2028 earnings at $0.15 EPS, Q4 2028 earnings at $0.13 EPS, FY2028 earnings at $0.60 EPS and FY2029 earnings at $0.66 EPS.

A number of other equities analysts have also recently issued reports on RDY. The Goldman Sachs Group cut shares of Dr. Reddy’s Laboratories from a “neutral” rating to a “sell” rating in a research report on Thursday, April 23rd. Weiss Ratings upgraded shares of Dr. Reddy’s Laboratories from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Dr. Reddy’s Laboratories presently has an average rating of “Hold” and an average price target of $16.90.

Dr. Reddy’s Laboratories Price Performance

RDY stock opened at $13.02 on Wednesday. The company has a 50 day simple moving average of $13.42 and a 200 day simple moving average of $13.78. The stock has a market cap of $10.86 billion, a price-to-earnings ratio of 22.44, a P/E/G ratio of 1.83 and a beta of 0.27. Dr. Reddy’s Laboratories has a 1 year low of $12.19 and a 1 year high of $16.17. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.80 and a quick ratio of 1.35.

Dr. Reddy’s Laboratories (NYSE:RDY) last issued its quarterly earnings results on Tuesday, May 12th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The firm had revenue of $852.55 million for the quarter, compared to the consensus estimate of $886.58 million. Dr. Reddy’s Laboratories had a return on equity of 12.34% and a net margin of 12.90%.

Institutional Investors Weigh In On Dr. Reddy’s Laboratories

Large investors have recently bought and sold shares of the stock. Robeco Institutional Asset Management B.V. lifted its stake in shares of Dr. Reddy’s Laboratories by 0.5% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 13,154,524 shares of the company’s stock valued at $184,690,000 after buying an additional 70,018 shares in the last quarter. Royal Bank of Canada lifted its position in shares of Dr. Reddy’s Laboratories by 4.6% during the first quarter. Royal Bank of Canada now owns 9,984,082 shares of the company’s stock valued at $138,293,000 after purchasing an additional 434,805 shares in the last quarter. Morgan Stanley lifted its position in shares of Dr. Reddy’s Laboratories by 41.2% during the fourth quarter. Morgan Stanley now owns 8,926,051 shares of the company’s stock valued at $125,322,000 after purchasing an additional 2,603,897 shares in the last quarter. Aikya Investment Management Ltd lifted its position in shares of Dr. Reddy’s Laboratories by 9.3% during the fourth quarter. Aikya Investment Management Ltd now owns 7,338,525 shares of the company’s stock valued at $103,033,000 after purchasing an additional 623,518 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its holdings in Dr. Reddy’s Laboratories by 2.0% during the third quarter. JPMorgan Chase & Co. now owns 6,027,710 shares of the company’s stock worth $84,267,000 after buying an additional 116,924 shares during the last quarter. 3.85% of the stock is currently owned by institutional investors and hedge funds.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Ltd. is an India?based multinational pharmaceutical company that develops, manufactures and markets a wide range of pharmaceutical products and services. Established in 1984 by the late Dr. Kallam Anji Reddy, the company has grown into a diversified healthcare enterprise offering generic and proprietary medicines, active pharmaceutical ingredients (APIs), biosimilars and custom research and manufacturing services (CRAMS). Its portfolio spans therapeutic areas such as oncology, cardiovascular care, dermatology, gastroenterology and pain management.

The company’s core activities include the development and commercialization of cost?effective generic treatments for branded drugs that have lost patent protection, along with in?house research into innovative molecule development.